CRA provided expert reports and trial testimony in trade secret litigation concerning an early-stage oncology product candidate. Plaintiff claimed that the alleged misappropriation led to accelerated development of a competing potential treatment. CRA quantified unjust enrichment using a methodology that measured the value associated with accelerated development, recognizing advantages associated with early versus late entry into the marketplace.
Update on the Texas Business Court: July 2025
The Texas Business Court was formed in September 2024 as a specialized court that aims to provide a more efficient and predictable environment for resolving...